Cargando…

Dalbavancin as suppressive antibiotic therapy in patients with prosthetic infections: efficacy and safety

Suppressive antibiotic therapy (SAT) is a strategy to alleviate symptoms and/or to reduce the progression of an infection when other treatment options cannot be used. Dalbavancin, due to its prolonged half-life, enables (bi) weekly dosing. Here, we report our multicenter real-life clinical experienc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ruiz-Sancho, Andrés, Núñez-Núñez, María, Castelo-Corral, Laura, Martínez-Marcos, Francisco Javier, Lois-Martínez, Nagore, Abdul-Aziz, Mohd Hafiz, Vinuesa-García, David
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10337584/ https://www.ncbi.nlm.nih.gov/pubmed/37448966 http://dx.doi.org/10.3389/fphar.2023.1185602

Ejemplares similares

Long-Term Suppressive Therapeutic-Drug-Monitoring-Guided Dalbavancin Therapy for Cardiovascular Prosthetic Infections
por: Gallerani, Altea, et al.
Publicado: (2023)

Dalbavancin for the Treatment of Prosthetic Joint Infections: A Narrative Review
por: Buzón-Martín, Luis, et al.
Publicado: (2021)

Corynebacterium striatum Prosthetic Joint Infection Successfully Treated with Long-Term Dalbavancin
por: Söderquist, Bo, et al.
Publicado: (2023)

Ototoxicity associated with extended dalbavancin treatment for a shoulder prosthetic joint infection
por: Lange, Anna, et al.
Publicado: (2023)

Dalbavancin
por: Barberán, José, et al.
Publicado: (2021)

DALBACEN cohort: dalbavancin as consolidation therapy in patients with endocarditis and/or bloodstream infection produced by gram-positive cocci
por: Hidalgo-Tenorio, Carmen, et al.
Publicado: (2019)

Suppressive Antibiotic Treatment in Prosthetic Joint Infections: A Perspective
por: Cobo, Javier, et al.
Publicado: (2021)

Anti-cooperative ligand binding and dimerisation in the glycopeptide antibiotic dalbavancin
por: Cheng, Mu, et al.
Publicado: (2014)

Determination of the Elution Capacity of Dalbavancin in Bone Cements: New Alternative for the Treatment of Biofilm-Related Peri-Prosthetic Joint Infections Based on an In Vitro Study
por: Sánchez-Somolinos, Mar, et al.
Publicado: (2022)

Serum Bactericidal Activity Levels Monitor to Guide Intravenous Dalbavancin Chronic Suppressive Therapy of Inoperable Staphylococcal Prosthetic Valve Endocarditis: A Case Report
por: Spaziante, Martina, et al.
Publicado: (2019)

Global trends of dalbavancin: A bibliometric analysis
por: Monteagudo‐Martínez, Nuria, et al.
Publicado: (2022)

Comparison of Sequential Dalbavancin With Standard-of-Care Treatment for Staphylococcus aureus Bloodstream Infections
por: Molina, Kyle C, et al.
Publicado: (2022)

Toxicology of antimicrobial nanoparticles for prosthetic devices
por: Nuñez-Anita, Rosa Elvira, et al.
Publicado: (2014)

Dalbavancin: a novel antimicrobial
por: Chen, A Y, et al.
Publicado: (2007)

1286. Evaluating Dalbavancin Suppression Therapy in Patients at High Risk for Recurrent Infections
por: Shaw, Michael, et al.
Publicado: (2023)

Dalbavancin: A Novel Lipoglycopeptide Antibiotic with Extended Activity Against Gram-Positive Infections
por: Smith, Jordan R., et al.
Publicado: (2015)

Dalbavancin for treating prosthetic joint infections caused by Gram-positive bacteria: A proposal for a low dose strategy. A retrospective cohort study
por: Martín, Luis Buzón, et al.
Publicado: (2019)

Emerging resistance in Staphylococcus epidermidis during dalbavancin exposure: a case report and in vitro analysis of isolates from prosthetic joint infections
por: Al Janabi, Jasmina, et al.
Publicado: (2023)

Characterization of Mechanical Allodynia and Skin Innervation in a Mouse Model of Type-2 Diabetes Induced by Cafeteria-Style Diet and Low-Doses of Streptozotocin
por: Castañeda-Corral, Gabriela, et al.
Publicado: (2021)

Vibrational Optical Activity Study of Four Antibiotic (Lipo)glycopeptides: Vancomycin, Oritavancin, Dalbavancin, and Teicoplanin
por: Aerts, Roy, et al.
Publicado: (2022)

Efficacy of Antibiotic Suppressive Therapy in Patients with a Prosthetic Joint Infection
por: Wouthuyzen-Bakker, Marjan, et al.
Publicado: (2017)

Targeting Dalbavancin Inoculum Effect: Adjunctive Single Dose of Daptomycin
por: Kebriaei, Razieh, et al.
Publicado: (2023)

Effect of savirin in the prevention of biofilm-related Staphylococcus aureus prosthetic joint infection
por: Pant, Narayan, et al.
Publicado: (2022)

Long-term Dalbavancin for Suppression of Gram-Positive Chronic Left Ventricular Assist Device Infections
por: Rowe, Sarah, et al.
Publicado: (2023)

Evolution of Antibiotic Tolerance During Oxacillin, Daptomycin and Dalbavancin Therapy Results in Breakthrough Staphylococcus aureus Bacteremias
por: Berti, Andrew, et al.
Publicado: (2017)

Dalbavancin Use in Vulnerable Patients Receiving Outpatient Parenteral Antibiotic Therapy for Invasive Gram-Positive Infections
por: Bork, Jacqueline T., et al.
Publicado: (2019)

Chronic prosthetic joint infections with a draining sinus. Who should receive suppressive antibiotic treatment?
por: Lensen, Karel-Jan, et al.
Publicado: (2020)

1829. Dalbavancin versus standard of care as directed therapy for Staphylococcus aureus bacteremia in patients unable to receive OPAT
por: Frazier, J, et al.
Publicado: (2022)

Contemporary Prosthetic Joint Infection Management: Is There a Role for Suppressive Antibiotic Therapy?
por: Sandiford, Nemandra A., et al.
Publicado: (2021)

Editorial: Modulating Vascular Lymphatic Growth in Disease: Current and Potential Pharmacological Approaches for Prevention and Treatment
por: Martinez-Corral, Ines, et al.
Publicado: (2022)

Editorial: Modulating lymphatic vascular growth in disease: current and potential pharmacological approaches for prevention and treatment, Volume II
por: Trevaskis, Natalie L., et al.
Publicado: (2023)

267 Dalbavancin for the treatment of Streptococcal Skin Infections
por: Puttagunta, Sailaja, et al.
Publicado: (2014)

Successful Treatment of Diabetic Foot Osteomyelitis with Dalbavancin
por: Loupa, Chariclia V., et al.
Publicado: (2020)

Dalbavancin: novel candidate for COVID-19 treatment
por: Hoffmann, Markus, et al.
Publicado: (2021)

Evaluating the Use of Dalbavancin for Off-Label Indications
por: Taylor, Katherine, et al.
Publicado: (2022)

The Effect of Dalbavancin in Moderate to Severe Hidradenitis Suppurativa
por: Molinelli, Elisa, et al.
Publicado: (2022)

Dalbavancin for Staphylococcus aureus Bacteremia: Are We There Yet?
por: Mahatanan, Rattanaporn, et al.
Publicado: (2023)

2902. Dalbavancin Use in Bone and Joint Infections
por: Sanikommu, Srivani, et al.
Publicado: (2023)

2764. Experience with dalbavancin in a pediatric hospital
por: Leon, Maria Deza, et al.
Publicado: (2023)

Levofloxacin: Insights Into Antibiotic Resistance and Product Quality
por: Izadi, Ensieh, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_ot1emgavle11taoum5pdfgt4a4